About secukinumab
Interleukin-17A inhibitor
Used for
- Plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis and non-radiographic axial spondyloarthritis
- Hidradenitis suppurativa
Usual adult dose
Usually injected under the skin weekly for five doses, then every four weeks; schedules vary by condition.
Usual dose in children
For plaque psoriasis in children aged 6 years and older, dosing is weight-based, often weekly initially then every four weeks. Some other uses have age and weight restrictions.
Common side effects
- Upper respiratory infections
- Diarrhea
- Injection-site reactions
- Oral or genital yeast infections
Important warnings
- May increase infection risk; tuberculosis screening is needed before treatment.
- Avoid live vaccines during treatment.
- May worsen inflammatory bowel disease or trigger new symptoms.
- Seek prompt assessment for serious infection or allergic reaction.
Pregnancy
Human pregnancy data are limited; use requires weighing potential risks and benefits.
Breastfeeding
It is unknown whether secukinumab passes into breast milk; discuss potential risks and benefits with a clinician.
Interactions
- Live vaccines may cause infection and should be avoided.
- Other biologic immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.